We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today data from a Phase II clinical trial demonstrating that its ultra rapid acting intranasal insulin was both...
Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) today reported financial results for the quarter ended March 31, 2008. Revenue for the three months ended March 31, 2008...
Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that its first quarter financial results will be released on Thursday, May 8, 2008, at 4:00 p.m. Eastern Time...
Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that it has entered into definitive agreements with new and existing investors to raise gross proceeds of...
Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that G?nter Blobel, M.D., Ph.D., has joined the Scientific Advisory Board of MDRNA, Inc., Nastech?s...
Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that Narendra Vaish, Ph.D., MBA, Senior Research Scientist and Group Leader ? RNAi Platform Technologies, will...
Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK), in compliance with Nasdaq Marketplace Rule 4350(b)(1)(B), which requires separate disclosure of receipt of an audit opinion...
Wall Street Media is presenting an exclusive highlight video from the presentation of Dr. Gordon Brandt, president of Nastech Pharmaceutical Company (NASDAQGM: NSTK) from the...
Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) today reported financial results for the fourth quarter and year ended December 31, 2007. Revenue for the three months...
Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that it will present at the Invest Northwest CEO & Investor Forum on Tuesday, March 18, 2008, at 4:30 p.m...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions